ActivX: Probing proteomics

A problem facing companies in the proteomics space is the gap between the data proteomics companies generate and the therapeutic relevance of those data. Many technologies do not provide information on whether a given protein is active or inactive in a disease state. In addition, low abundance proteins may go undetected, and thus potential therapeutics remain undiscovered.

ActivX Biosciences Inc. is working to address both issues with its high throughput chemistry-based

Read the full 704 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE